Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

ADC Shows Effectiveness in SCLC

DOI: 10.1158/2159-8290.CD-NB2015-144 Published December 2015
  • Article
  • Info & Metrics
Loading

An experimental antibody–drug conjugate (ADC) showed efficacy in an early-phase trial involving patients with relapsed or refractory small cell lung cancer (SCLC), according to results presented recently at the 2015 European Cancer Congress in Vienna, Austria. Researchers say the findings will spur additional studies because these patients have so few treatment options.

In the phase I trial, 73 patients with recurrent SCLC were given rovalpituzumab tesirine (Rova-T; Stemcentrx), an ADC that binds to the ligand of delta-like protein 3 (DLL3), an atypical Notch ligand. Among 27 confirmed DLL3-high positive patients, 44% had a partial response and 34% achieved stable disease compared with 23% and 68%, respectively, in unselected patients, indicating that DLL3-high expression may be a biomarker of response. Further, in the third-line setting, for which there are no approved treatment options, the response rate was 45% in patients whose tumors had DLL3-high expression.

“The high response rates in DLL3-positive patients are remarkable,” says M. Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, NY, who presented the findings. “The fact that there is a possible biomarker to predict response is significant because for the first time, we actually may be able to target SCLC. In the past, numerous studies have failed to identify biomarkers in this malignancy.”

SCLC, which accounts for about 14% of all lung cancers and has a 5-year survival rate of about 6%, is often diagnosed after it has metastasized, and most patients develop resistance to chemotherapy and radiation. Only one chemotherapy drug, topotecan, is approved as a second-line therapy.

Rova-T consists of three components: an antibody, a linker, and a cytotoxic payload. The antibody portion recognizes and binds to cell surface–available Notch ligand DLL3—overexpressed in approximately 70% of SCLCs. Once inside the cell, the linker is cleaved off, resulting in release of the cytotoxic agent pyrrolobenzodiazepine, which cross-links DNA to cause DNA damage and cell death.

“Rova-T is not a Notch pathway inhibitor,” says Pietanza. “Instead, it uses the Notch ligand to enter the cell and deliver chemotherapy directly to the tumor.”

The median duration of response among the 27 DLL3-positive patients was 178 days at data cutoff. “Toxicity was manageable at the maximum tolerated doses of 0.2 mg/kg every 3 weeks and 0.3 mg/kg every 6 weeks. The most commonly reported treatment-related adverse events were fatigue, peripheral edema, rash, thrombocytopenia, pleural effusion, and nausea.”

“The activity of the drug that we have seen is impressive,” says Pietanza. “Importantly, the durable, long-term responses are notable in such an aggressive disease, where progression is normally very rapid.”

A phase II trial of Rova-T for patients with SCLC is slated to launch in January 2016.

  • ©2015 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ADC Shows Effectiveness in SCLC
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ADC Shows Effectiveness in SCLC
Cancer Discov December 1 2015 (5) (12) OF4; DOI: 10.1158/2159-8290.CD-NB2015-144

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ADC Shows Effectiveness in SCLC
Cancer Discov December 1 2015 (5) (12) OF4; DOI: 10.1158/2159-8290.CD-NB2015-144
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Congress Approves Increase in Cancer Funding
  • Tasmanian Devil Facial Tumor Disease Turns Endemic
  • Proteomics Sharpens Brain Tumor Genomic Analysis
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement